TrialAdvances in therapy2015

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Hiroaki Iijima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.